| 261 |
SPIRIT-III: Clinical, Angiographic and IVUS Results from the Pivotal United States Randomized SPIRIT-III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients With Coronary Artery Disease |
Gregg W. Stone |
May. 25. 07 |
| 260 |
Drug-Eluting Stent Restenosis: First Large, Multicenter Prospective Report of Treatment Strategies and Clinical Outcomes in the US From the Strategic Transcatheter Evaluation of New Therapies (STENT) Group |
Charles A. Simonton |
May. 25. 07 |
| 259 |
DECLARE-Diabetes: Drug Eluting Stent Followed by Cilostazol Treatment Reduces Late Restenosis in Patient with Diabetes Mellitus |
Seong-Wook Park |
May. 25. 07 |
| 258 |
ACUITY PCI: A Prospective Trial of Patients With Acute Coronary Syndromes Undergoing PCI After Randomization to Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibitors: 30-Day Clinical and Angiographic Core Laboratory Results |
Gregg W. Stone |
May. 25. 07 |
| 257 |
TAXUS Real-World Experience from ARRIVE Registry |
Alan C. Yeung |
May. 25. 07 |
| 256 |
The Problem Is Exaggerated: Data From "Real-World" Registries |
Antonio Colombo |
May. 18. 07 |
| 255 |
Renal Failure and Contrast Nephropathy: An Overview and Considerations in the PCI Patient |
Roxana Mehran |
May. 18. 07 |
| 254 |
Is There a Safety Advantage in the PC Based DES Systems? Possible Mechanisms |
Alan C. Yeung |
May. 18. 07 |
| 253 |
The Baseline Clinical Features and Plaque Characteristics from the PROSPECT Trial |
Gregg W. Stone |
May. 18. 07 |
| 252 |
New DES Drug Carrier Systems: Biostable, Bioabsorbable, and No Polymers, Elution Kinetics, and Beyond! |
Martin Bert Leon |
May. 11. 07 |
